These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25633684)

  • 1. Ebola vaccine is safe and immunogenic, results show.
    Gulland A
    BMJ; 2015 Jan; 350():h524. PubMed ID: 25633684
    [No Abstract]   [Full Text] [Related]  

  • 2. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.
    Martin JE; Sullivan NJ; Enama ME; Gordon IJ; Roederer M; Koup RA; Bailer RT; Chakrabarti BK; Bailey MA; Gomez PL; Andrews CA; Moodie Z; Gu L; Stein JA; Nabel GJ; Graham BS
    Clin Vaccine Immunol; 2006 Nov; 13(11):1267-77. PubMed ID: 16988008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early trials of Ebola vaccine show immune response.
    Mayor S
    BMJ; 2015 Apr; 350():h1844. PubMed ID: 25855620
    [No Abstract]   [Full Text] [Related]  

  • 5. Approaches to demonstration of Ebola virus vaccine efficacy.
    Krause PR; Cavaleri M; Coleman G; Gruber MF
    Lancet Infect Dis; 2015 Jun; 15(6):627-9. PubMed ID: 26008825
    [No Abstract]   [Full Text] [Related]  

  • 6. Ebola Vaccines Safe and Immunogenic in 2 Trials.
    Slomski A
    JAMA; 2023 Jan; 329(4):278-279. PubMed ID: 36692563
    [No Abstract]   [Full Text] [Related]  

  • 7. Ebola vaccine success.
    Mullard A
    Nat Rev Drug Discov; 2017 Feb; 16(2):77. PubMed ID: 28148944
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
    Anywaine Z; Whitworth H; Kaleebu P; Praygod G; Shukarev G; Manno D; Kapiga S; Grosskurth H; Kalluvya S; Bockstal V; Anumendem D; Luhn K; Robinson C; Douoguih M; Watson-Jones D
    J Infect Dis; 2019 Jun; 220(1):46-56. PubMed ID: 30796818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-vectored Ebola vaccines.
    Gilbert SC
    Expert Rev Vaccines; 2015; 14(10):1347-57. PubMed ID: 26289977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.
    Mire CE; Geisbert TW
    Trends Mol Med; 2017 Aug; 23(8):669-671. PubMed ID: 28697885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ebola: The great ape gamble.
    Willyard C
    Nature; 2017 Mar; 543(7647):S56-S57. PubMed ID: 28355186
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunology of protection from Ebola virus infection.
    Krause PR; Bryant PR; Clark T; Dempsey W; Henchal E; Michael NL; Regules JA; Gruber MF
    Sci Transl Med; 2015 May; 7(286):286ps11. PubMed ID: 25947159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A DNA vaccine for the prevention of Ebola virus infection.
    Dery M; Bausch DG
    Curr Opin Mol Ther; 2008 Jun; 10(3):285-93. PubMed ID: 18535936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
    Agnandji ST; Huttner A; Zinser ME; Njuguna P; Dahlke C; Fernandes JF; Yerly S; Dayer JA; Kraehling V; Kasonta R; Adegnika AA; Altfeld M; Auderset F; Bache EB; Biedenkopf N; Borregaard S; Brosnahan JS; Burrow R; Combescure C; Desmeules J; Eickmann M; Fehling SK; Finckh A; Goncalves AR; Grobusch MP; Hooper J; Jambrecina A; Kabwende AL; Kaya G; Kimani D; Lell B; Lemaître B; Lohse AW; Massinga-Loembe M; Matthey A; Mordmüller B; Nolting A; Ogwang C; Ramharter M; Schmidt-Chanasit J; Schmiedel S; Silvera P; Stahl FR; Staines HM; Strecker T; Stubbe HC; Tsofa B; Zaki S; Fast P; Moorthy V; Kaiser L; Krishna S; Becker S; Kieny MP; Bejon P; Kremsner PG; Addo MM; Siegrist CA
    N Engl J Med; 2016 Apr; 374(17):1647-60. PubMed ID: 25830326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single shot against Ebola and Marburg virus.
    Baize S
    Nat Med; 2005 Jul; 11(7):720-1. PubMed ID: 16015361
    [No Abstract]   [Full Text] [Related]  

  • 17. First Ebola virus vaccine to protect human beings?
    Geisbert TW
    Lancet; 2017 Feb; 389(10068):479-480. PubMed ID: 28017402
    [No Abstract]   [Full Text] [Related]  

  • 18. How Ebola-vaccine success could reshape clinical-trial policy.
    Butler D; Callaway E; Check Hayden E
    Nature; 2015 Aug; 524(7563):13-4. PubMed ID: 26245556
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.
    Zhou Y; Sullivan NJ
    Curr Opin Immunol; 2015 Aug; 35():131-6. PubMed ID: 26247875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
    Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
    Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.